TP53 and breast carcinoma: Yet, both p53 SMWC were more effective against ALDHbright cells than cisplatin when tested against the human breast carcinoma cell line SUM149 and endometrial carcinoma cell line Ishikawa, both expressing mutant p53, or gemcitabine when tested against the pancreas carcinoma cell line Pan02 expressing WT p53 (Figure 2 panel B and C).